Effect of pH on the equilibrium dialysis of phenytoin suspension with and without enteral feeding formula.
Significant decreases have been reported in phenytoin absorption when the suspension is combined with continuous enteral feedings. Several theories for this interaction have been proposed including binding of phenytoin to the protein constituents of the enteral formula, phenytoin binding to the calcium in the enteral formula, and inadequate dissolution of the suspension when delivered with the enteral formula due to the high pKa of phenytoin and the acidic nature of the enteral formula. We therefore evaluated the effects of pH levels 2.0, 3.5, 6.0, and 8.0 on the interaction of phenytoin suspension with enteral formula (Osmolite) with equilibrium dialysis using a Spectra/Por 1 (MWCO 6000-8000) molecularporous dialysis membrane. Phenytoin concentrations in the dialysis membrane (internal phase) mimicked the expected stomach concentrations of a 100-mg dose administered in an adult stomach containing 200 ml of gastric fluid. External phase buffers were sampled at 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, and 24.0 hr after the start of the dialysis. The phenytoin concentrations in the external phase were compared between buffer alone or buffer combined with enteral formula at the same pH and time intervals. With pH 2.0 and 3.5 the enteral formula formed an aggregate with suspension whereas no aggregate was formed with pH 6.0 and 8.0. The phenytoin concentrations with pH 2.0 were 26% to 44% lower and with pH 3.5 were 11.5 to 27% lower when phenytoin suspension was combined with enteral solution. However, at 24 hr there was no difference between the two conditions with both pH 2.0 and 3.5.(ABSTRACT TRUNCATED AT 250 WORDS)
Splinter
M Y
MY
Section of the Pharmacy Practice, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City 73190.
Seifert
C F
CF
Bradberry
J C
JC
Tu
Y H
YH
Allen
L V
LV
D003956:Dialysis; D004750:Enteral Nutrition; D005526:Food, Formulated; D006863:Hydrogen-Ion Concentration; D008567:Membranes, Artificial; D010672:Phenytoin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011485:Protein Binding
D008567:Membranes, Artificial; D010672:Phenytoin